Vanflyta (quizartinib) — United Healthcare
Acute myeloid leukemia (AML)
Initial criteria
- Diagnosis of acute myeloid leukemia (AML)
- Disease is FLT3 internal tandem duplication (ITD) positive
- One of the following: Vanflyta will be used in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy OR Vanflyta will be used for patients with relapsed/refractory disease as a component of repeating the initial successful induction regimen or as a single agent
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Vanflyta therapy
Approval duration
12 months